Caris Life Sciences Inc. (NASDAQ:CAI) shares are up during Friday’s premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company’s Achieve 1 study.

Sales More Than Doubled

Caris Life Sciences on Thursday reported fourth-quarter earnings of 28 cents compared to the consensus loss of 3 cents.

Sales for the quarter jumped 125% year over year to $292.89 million, beating the consensus of $208.63 million.

The increase was driven primarily by a 199% growth in molecular profiling services revenue, which was $282.1 million, attributable to an increase in total clinical case volume and ASP improvements across therapy selection solutions.

The company completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% year over year, consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.

Reported gross margin of 75%, an approximate 2,000 bps improvement.

The company reported positive Adjusted EBITDA of $106.1 million, a shift from a loss of $23 million.

“Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris…,” said David Dean Halbert, Founder, Chairman, and CEO of Caris Life Sciences.

Outlook

Caris Life Sciences expects fiscal 2026 sales between $1 and $1.02 billion versus the consensus of $1.198 billion.

Caris Life Sciences expects operating expenses of $590 million-$595 million, representing a 19% to 20% increase due to commercial expansion and an increase in pipeline trial activities, and expects to remain positive on Free Cash Flow and Adjusted EBITDA.

Caris’ Cancer Test Shows Superiority Versus Traditional Methods

The company reported advancements in its multi-cancer early detection test, Caris Detect, which utilizes Whole Genome Sequencing to enhance early cancer detection capabilities, adding pressure as broader markets edged lower.

The interim readout of Achieve 1 supports the upcoming launch of Caris Detect.

The interim readout highlighted Caris Detect’s superiority in sensitivity and specificity compared to traditional methods, with the study involving approximately 1,505 samples from undiagnosed patients. The company expects to release further results from the blinded validation phase later in the first quarter of 2026.

In addition, Caris has processed over one million cases, generating more than 50 billion molecular markers, which underscores its robust data foundation for AI-driven cancer detection.

Recent Analyst Actions

The stock carries a Buy Rating with an average price target of $33.63. Recent analyst moves include:

• Baird: Initiated with Outperform (Target $26.00) (Feb. 17)
• Canaccord Genuity: Hold (Raises Target to $30.00) (Dec. 22, 2025)

CAI Price Action: Caris Life Sciences shares were up 20.43% at $23.17 during premarket trading on Friday, according to Benzinga Pro data.

Photo via Shutterstock